Unicorn Capital Partners

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Tezign is a leading enterprise content and AI company founded in 2015, specializing in generative AI solutions for content creation and management. The company focuses on building a digital infrastructure that enhances the efficiency and quality of content production for global enterprises. Tezign has partnered with over 200 notable companies, including major brands like Alibaba, Unilever, and Procter & Gamble, and has successfully generated more than 150,000 content assets. Its platform employs advanced data technology and image recognition to connect top designers with businesses, facilitating marketing content production and optimization. Additionally, Tezign has cultivated a content ecosystem comprising over 100,000 content creators, establishing a significant scale in content asset management.

Botkin.AI is a Moscow-based software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015, the company focuses on developing advanced tools for healthcare providers to enhance the diagnosis of oncological diseases. Its platform employs deep machine learning to analyze medical images, such as radiograms, and assess the risk of tumors, particularly lung cancer, at early stages with high accuracy. By streamlining the analysis of clinical data, Botkin.AI enables radiologists to diagnose tumors more effectively and efficiently, improving patient outcomes without compromising the quality of medical conclusions.